强生公司 (JNJ.US) 2026年第三季度业绩电话会
文章語言：
简
繁
EN
分享
紀要
原文
会议摘要
Johnson & Johnson reported strong Q3 2026 financial results, with 6% operational sales growth driven by innovative medicines in oncology, immunology, and neuroscience. Despite MedTech challenges, the company remains optimistic, projecting double-digit growth by decade's end through strategic investments and a robust pipeline. Upcoming product launches and clinical trials are expected to reinforce growth, with full-year guidance raised to 7.2%-7.6% operational sales growth.
会议速览
Johnson & Johnson's Q3 2026 Earnings Call Highlights Business Performance and Future OutlookJohnson & Johnson's Q3 2026 earnings call discussed business performance, growth drivers, sales results, and updated guidance, acknowledging strategic partnerships and forward-looking statements. The call covered sales and P&L, capital allocation, and market position, emphasizing risks and uncertainties affecting future outcomes.
Johnson & Johnson's Q3 Sales Growth and Pipeline Advances in Oncology, Immunology, and NeuroscienceJohnson & Johnson reported Q3 operational sales growth, exceeding analyst expectations. The company highlighted advancements in oncology, immunology, and neuroscience, including new therapies and acquisitions, aiming for accelerated growth and a focus on patient needs. Mete segment fell short but remains a priority for future growth.
Johnson & Johnson's Q3 Report Highlights: Cardiovascular Innovations, Robot-Assisted Surgery, and Vision AdvancementsJohnson & Johnson's Q3 report showcases significant growth in cardiovascular technologies, including circulatory restoration and heart recovery solutions. Notably, the company achieved a milestone with over 100,000 patients treated using the posted field ablation platform. The approval of Body Pulse Pro in Japan and the FDA's novel authorization for Kava, a soft tissue robotic system, underscore the company's commitment to innovation. In vision care, the launch of Techs PC and advancements in personalized bison solutions reflect ongoing progress. These achievements highlight Johnson & Johnson's strategic focus on high-growth areas, driving breakthroughs in patient care and reinforcing its position in the healthcare industry.
Q3 2026 Financial Results: Global Sales and Earnings AnalysisQ3 2026 saw worldwide sales of $25.4 billion, a 6% increase, with innovative medicines leading growth at 7.9%. Earnings were $210 million, impacted by litigation and transaction expenses. MedTech sales were $8.6 billion, with electrophysiology and contact lenses showing strong performance. Cardiovascular and surgery segments faced declines, while orthopedics and ophthalmic products saw positive growth.
Q3 Financials Highlight Growth Amid Strategic Investments and Medtech ChallengesThe dialogue covers Q3 financial highlights, emphasizing growth driven by new product launches and strong commercial execution. Despite headwinds in certain MedTech areas, the company raised its guidance for Ly, citing portfolio momentum and upcoming pipeline catalysts. Investments in oncology, in vivo CAR T therapies, and a disciplined capital allocation strategy underscore confidence in achieving double-digit growth by decade's end.
Update on Financial Guidance, OVC Litigation Resolution, and Q4 OutlookAnnounced a $5.5 billion OVC T litigation resolution, raised operational sales guidance for the year, tightened ranges for operating margin, net interest expense, and effective tax rate, and outlined impacts of Firefly bio and sale biomedicines on future earnings per share.
Upcoming Developments and Growth Outlook in Oncology, Immunology, and MedTechThe dialogue highlights several upcoming data readouts and approvals in oncology, immunology, and MedTech, including pareta M, J and J ng, Alexa, rival ramp FA Pro, ecotage, araullo Pro, aviom me's Impella CP pump, and otava. It emphasizes strong adoption of existing products, investment in clinical evidence, and the goal of establishing otava as a significant surgery portfolio pillar by the end of the decade.
Pew Separation Plan on Track for 2027, Spin-Off Considered Best Option for Shareholder ValueThe company's strategy for separating the Pew division remains on schedule for mid-2027, with a spin-off now seen as the optimal method to enhance long-term shareholder value. Progress in evaluating separation options has positioned the company well, and upcoming updates will include insights into growth drivers and pipeline innovations. A business review event is planned for December to showcase advancements and future growth potential, emphasizing dedication to innovation and improved patient outcomes.
Internal Investments Drive Double-Digit Growth, Urgency to Enhance PortfolioDiscussion centered on internal strategic investments propelling double-digit growth by decade's end, excluding M&A. Urgency highlighted to improve existing portfolio performance, with confidence in long-term growth potential despite short-term challenges.
2027 Sales Growth and Earnings Projections Post IP RD AdjustmentsA discussion on projected sales and earnings growth for 2027, adjusting for IP RD impacts and considering margin improvements from business separations and technological advancements.
Update on Icotinib's Launch Success and Future Indication ExpansionsDiscusses Icotinib's strong psoriasis launch with over 20,000 patients initiated, expanding systemic market share, and plans for additional indication approvals, projecting it as a major asset.
Medtech's Resilience Amid Challenges: Strategies for Recovery and GrowthDespite Q3 underperformance, Medtech remains confident in underlying procedure environment stability and innovative solutions. Key strategies include addressing known headwinds, leveraging US market growth, and launching new products like Varials Pro and Otava. Short-term headwinds are expected to moderate, supporting improved performance and positioning for stronger results in Q4 and beyond.
Strategies for Icotinib Launch in IBD: Leveraging Psoriasis Success and Dual Therapy DevelopmentDiscusses leveraging psoriasis launch success for icotinib's IBD introduction, emphasizing unmet needs, early access, and dual therapy potential to address refractory patients, enhancing market expansion and efficacy perception among physicians.
Expanding Market Opportunities and Clinical Success of Inle and ICO TiThe dialogue highlights significant market potential and clinical achievements for Inle and ICO Ti, emphasizing sequential growth, high remission rates, and opportunities in broader patient populations, aiming for a $5 billion plus platform expansion.
Oral Drug Efficacy and Vaccine Confidence in Medical StudiesThe dialogue discusses the potential efficacy of oral drugs in IBD treatment and confidence in vaccine outcomes, highlighting brisk enrollment in trials and the anticipation of significant results in secondary stroke and atrial fibrillation studies.
Oral Anticoagulation Therapy Safety and International Medtech Business DynamicsDiscusses the necessity for safer oral anticoagulation therapy, highlighting a significant patient gap due to bleeding risks. Also, explores impacts of geopolitical dynamics on international medtech sales, noting short-term disruptions but maintaining confidence in long-term market stability.
Johnson & Johnson's Medtech Strategy: Innovation, Growth, and Surgical RoboticsJohnson & Johnson's medtech division emphasizes growth through innovation, particularly in wound closure and surgical robotics, with confidence in future expansion, especially in EMEA, driven by strategic portfolio transformation and upcoming product launches.
Johnson & Johnson Prepares for Early Line Therapy Shifts in Myeloma TreatmentJohnson & Johnson discusses strategies for educating physicians about earlier use of their product in myeloma treatment, highlighting growth in early line settings and upcoming trials. The company emphasizes potential market share gains from existing regimens, showcasing impressive survival data and patient outcomes. They also outline future growth opportunities in medical innovation, positioning J&J as a leader in healthcare growth.
要点回答
Q：What are the key topics covered in the Johnson & Johnson third quarter 2026 earnings conference call?
A：The key topics covered in the Johnson & Johnson third quarter 2026 earnings conference call include business performance and growth drivers, operational sales growth, strategic focus areas in various therapeutic areas, and an overview of capital allocation priorities and updated guidance.
Q：What was the overall operational sales growth reported for the third quarter of 2026?
A：The overall operational sales growth reported for the third quarter of 2026 was 7.9%.
Q：What progress is being made in the oncology business and which therapies have seen significant adoption?
A：In the oncology business, progress includes growing the multiple myeloma portfolio, with new Phase I results demonstrating the effectiveness of a combination therapy. The acquisition of Firefly Bi added a platform for difficult-to-treat cancers. The oncology company is aiming for number one status by 2030 with sales projected to exceed $50 billion.
Q：How has the neuropsychiatry business performed and what are the growth drivers?
A：The neuropsychiatry business has seen exceptional sales growth, with Kalita reaching $1 billion in year-to-date sales and becoming the fastest-growing oral branded therapy for major depressive disorder. This growth is driven by the product's use as an adjunct treatment for major depressive disorder and its significant and rapid improvement in symptoms.
Q：What are the key contributions of the cardiovascular segment?
A：The cardiovascular segment's key contributions include addressing the leading global cause of death through investments in heart recovery, circulatory restoration, and heart rhythm disorders. This was another strong quarter for Shock Wave, and the ongoing global launch of Sublime to Ablate continues to expand the reach of the intravascular lithi C vipo.
Q：What is the latest advancement in the company's digital health offerings?
A：The latest advancement in the company's digital health offerings is the FDA novel authorization for Kava, the world's first stable integrated soft tissue robotic system. This innovation is part of the company's efforts to bring significant technological advancements to market this decade.
Q：What financial results were reported for the third quarter of 2026?
A：The financial results reported for the third quarter of 2026 include worldwide sales of $25.4 billion, an increase of 6% from the prior year. In the US, sales grew by 11.1%, and diluted earnings per share were 9 cents, impacted by various litigation resolutions and expenses related to recent transactions.
Q：What factors contributed to the growth of Alita and Medtech world sales?
A：Alita's growth was 9.4%, which came from continued share gains and market growth, partially offset by favorable patient mix within immunology. The Medtech world sales of $8.6 billion were up 2.5%, with growth from four point percent in the US and 0.1% outside the US, primarily driven by cardiovascular growth of 4.1% including 20 basis points related to acquisitions.
Q：What were the major drivers for the decline in the cardiovascular segment's performance?
A：The cardiovascular segment's performance declined by 5.2%, which was attributed to lower patient volume and competitive pressures from biosimilars, partially offset by new product performance and commercial execution.
Q：What was the overall growth rate of the company's surgical business and what factors contributed to it?
A：The surgical business saw a decline in script with a negative impact from divestitures, but the decline was partially offset by portfolio strength in recent innovation and commercial execution. Contact lenses and other products grew 4.3%, driven by strong performance in the accuvote oasis one day family of products, solidifying the company's leadership position.
Q：What were the key financial results for the third quarter mentioned in the transcript?
A：Key financial results for the third quarter included cost of goods sold deleveraged by 15 basis points, selling, marketing, and administrative expenses flat as a percent of sales, and research and development investments of approximately 18.3% of sales, including $1 billion related to the acquisition of Firefly Bio. Additionally, other income and expense was a net expense of $5.8 million, and the tax rate was a small net benefit, primarily due to the positive tax effect from the accrual for the proposed house litigation resolution.
Q：How does the company expect to perform financially in the remainder of the year and what are the updated sales guidance figures?
A：The company expects to perform financially by raising its guidance for the year and is confident in its full-year free cash flow guidance of $21 billion. The updated operational sales growth is in the range of script to script, with an expectation of $101.2 billion at the midpoint or growth of Ed Ed. The updated forecast for operating margin decline is approximately script basis points, and the effective tax rate is now estimated to be 17.0% to 17.5%. Adjusted operational earnings per share are expected to be in the range of $10.95 to $11.50, with a midpoint of $11.10 or growth of Ed Ed. The company is also anticipating several important data readouts in the fourth quarter that will reinforce its growth outlook.
Q：What are the expectations for the adoption and revenue contribution of Otava?
A：The expectation is for adoption and revenue contribution from Otava to build over time, aiming to establish it as a significant pillar of the surgery portfolio by the end of the decade.
Q：What is the significance of the Enterprise Business review event mentioned in December?
A：The Enterprise Business review event in December is significant as it will highlight the key drivers of growth by the end of the decade, including the earlier stage pipeline and the next wave of growth. Attendees will also experience the company's latest innovations, such as Otava.
Q：How does the company plan to achieve double-digit growth by the end of the decade?
A：The company plans to achieve double-digit growth by focusing on internal strategic investments in areas such as vision care, surgery, and expanding with products like Otava. They are also addressing challenges and performing clinical evidence to support the impact of their products.
Q：What is the company's position on the challenges faced by the TCI study outside the US?
A：The company views the challenges faced by the TCI study outside the US as short-term headwinds and not structural. They are focused on education and advancing clinical evidence to demonstrate the life-saving and improving impact of their product, Impella.
Q：What are the expectations for reported sales growth and earnings per share (EPS) in 2027?
A：Reported sales growth is expected to be similar to 2026 after adjusting for a extra week in both years, which would be approximately 5.4% reported growth in 2027. For EPS growth, it is anticipated to be a little bit better than sales growth after adjustments for the dilution impact.
Q：What is the current status of patient uptake for Icoty and its potential as a large asset?
A：Patients are actively initiating therapy with Icoty, with over 20,000 patients started and more than 8,000 prescribers. The launch is tracking better than most all other launches in systemic diseases, and the company sees it as one of their biggest assets in innovative medicine. They are expanding the market and have strong access and engagement with commercial plans. Future expectations include positive data readouts and continued expansion into other indications.
Q：What are the underlying fundamentals of Medtech and what needs to be done to improve the J&J franchise?
A：The underlying fundamentals of Medtech, including patient volumes, CapEx spending, and general flows, are considered solid. However, the company admits that their performance is below internal standards and communicated expectations. To improve the J&J franchise, the focus is on delivering stronger results starting from the fourth quarter onwards, with actions centered on improving the current performance.
Q：What factors contributed to the performance challenges outside of the US?
A：The performance challenges outside of the US were attributed to known headwinds such as the expected impact of a transformation program in surgery, the ongoing expansion of volume-based procurement in China, competitive intensity in electrophysiology, especially in Asia Pacific, and a new headwind related to the conflict in the Middle East.
Q：What new product launches have been made in electrophysiology and what future launch is anticipated?
A：In electrophysiology, the company has launched varials Pro in Europe, which is faster and easier to use, and has seen double-digit growth. The company is also set to launch veritables Pro in Japan after receiving regulatory approval, with the AUS launch expected by the end of the year.
Q：What issues were encountered in the cardiac market and what is the company's response?
A：The company encountered issues in the cardiac market related to the study in high-risk PCI. The methodology used in the study was believed not to follow well-established practices, which the company is addressing through education. The evidence base is considered solid, and the company anticipates that the business will return to growth shortly, despite Q3 not being a strong quarter for Mete.
Q：How does the company view the underlying procedure environment and what are their plans for future performance?
A：The company believes that the underlying procedure environment remains stable across key markets. Their focus is now on converting demand into more consistent performance. They remain confident in the combination of the momentum in the US and the moderation of near-term headwinds, which will support improved performance in Q4 and position the company for stronger performances in Ed and beyond.
Q：What insights are shared regarding the potential for Icty in treating psoriasis and its expansion into IBD?
A：The company is confident in Icty's potential for treating psoriasis, as evidenced by its successful launch and rapid growth. With regard to IBD, the company has a solid understanding of the space as shown by the positive start of the IBD launch. They recognize the large unmet need in many untreated or inadequately treated patients with IBD and see significant opportunity for market expansion with Icty, especially given its profile and the data that will emerge as it becomes available. The company also emphasizes the importance of early access and rapid uptake upon receiving positive data results.
Q：What future plans are there for Icty in the treatment of psoriasis and IBD?
A：Future plans for Icty in the treatment of psoriasis and IBD include expanding its use into larger patient populations. The company anticipates significant growth in the market for Icty based on current indications, with the potential to reach a 5 billion plus platform. They also have encouraging data from phase I studies, and are developing a combination therapy for patients not responsive to monotherapy, which could migrate patients from monotherapy to dual therapies. Additionally, there are plans to submit for label expansion based on the promising data from the Sunrise 3 study.
Q：What data is anticipated for Icty, and how is it expected to perform?
A：While the company has not disclosed any sales figures for Icty, they are confident in making such disclosures next year based on the current momentum and progress with the launch of Icty and other new products. They expect significant growth and see Icty and Alexa as key drivers of their growth acceleration, projecting double-digit growth for both products.
Q：What are the company's expectations for Alexa's role in treating bladder cancer and its potential market size?
A：The company expects Alexa to play a significant role in treating bladder cancer, especially in the papillary form of the disease, for which the company has already shown substantial efficacy data. The use of Alexa in the more common papillary form of bladder cancer is included in the NCCN guidelines. The company anticipates a greater opportunity with the broader patient population of 50,000 and the BCG naive population, potentially reaching a number in the 5 billion plus range for the platform.
Q：How does the company view the data from the partnership with GlaxoSmithKline, especially with the upcoming ssps data?
A：The company has shared confidence in the data from the partnership with GlaxoSmithKline, especially regarding the upcoming ssps data. They are optimistic about the similarity of the ssps data to the SMx data and the potential of the vaccine to be a significant product. However, specific details or confirmations about the ssps data were not disclosed.
Q：What is the theory about oil absorption and efficacy being determined by?
A：The theory under discussion pertains to the potential of a compound (presumably oil) to be a more potent inhibitor of factor Xi, which could impact the efficacy of oil absorption and potentially its therapeutic efficacy.
Q：Why is there a need for highly effective oral anticoagulation therapy?
A：There is a need for highly effective oral anticoagulation therapy due to the high proportion of patients eligible for such treatment who are not currently receiving it, largely due to concerns about potential safety and the risk of bleeding associated with existing oral anticoagulants.
Q：How has the situation in the Middle East impacted the international medtech business?
A：The situation in the Middle East has significantly impacted the international medtech business, resulting in increased disruption to ordering patterns, tender timing, and hospital spending decisions across multiple countries. Governments and healthcare systems have become more cautious, leading to delayed funding and procurement decisions, which has created a meaningful impact on purchasing behavior.
Q：What actions is the company taking internationally for the surgery business?
A：The company is taking unspecified actions internationally for the surgery business, as indicated by their focus on opportunities where they can make an impact despite headwinds. These actions are related to their confidence in the underlying clinical need and their belief that many opportunities are merely deferred rather than permanently lost.
Q：How does the company plan to benefit from the introduction of surgical robots?
A：The company plans to benefit from the introduction of surgical robots by entering the surgical robotics space, which they believe will allow them to participate more fully in an attractive and underpenetrated area of surgery. Their existing leadership positions in wound closure, surgery, and advanced instrumentation provide a strong foundation for this expansion.
Q：What is the potential for capturing share from existing frontline regimens for a new treatment?
A：The potential for capturing share from existing frontline regimens for a new treatment can be substantial, as evidenced by the substantial growth in the use of a product called cartive D in early-line settings. This growth is attributed to the product's access, familiarity, and its ability to achieve significant overall survival rates as early as the second line of therapy.
